Millennium: Blood-cancer drug trial yields positive results

03/14/2008 | Boston Globe (tiered subscription model), The

A drug cocktail composed of melphalan, prednisone and Velcade that was given to multiple myeloma patients resulted in high rates of complete remission and three-year survival, Millennium Pharmaceuticals reports. Developed by Millennium and Johnson & Johnson, Velcade is already approved for use in multiple myeloma patients who have undergone at least one prior treatment. The combination trial was in newly diagnosed patients deemed ineligible for stem cell transplants.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN